<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467242</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0372</org_study_id>
    <nct_id>NCT04467242</nct_id>
  </id_info>
  <brief_title>Right Ventricular Diastolic Dysfunction</brief_title>
  <acronym>RVDD</acronym>
  <official_title>Interaction Between Right Heart Dysfunction and Emphysema: Impact of Endoscopic Lung Volume Reduction (RVDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart-lung interactions remain misunderstood whereas pulmonary and cardiac pathologies are
      very commonly associated.

      Emphysema by increasing intrathoracic pressure appears to affect cardiac function.

      Interestingly, previous studies have shown a link between the telediastolic volume of the
      right ventricle (measured by RMI) and the intensity of emphysema.

      Our hypothesis is that the emphysema by increasing intrathoracic pressure leads to or
      accentuates right cardiac diastolic dysfunction by decreasing compliance and cardiac preload.

      To verify this hypothesis the investigators will perform KT loop procedures in order to
      acquire intracardiac pressure/volume curves before and after lung volume reduction.

      The pressure/volume curves allow the analysis of systolic and diastolic function, cardiac
      contractility and loading conditions.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the change in right diastolic cardiac function after reduction of emphysema</measure>
    <time_frame>1 day</time_frame>
    <description>Estimate the change in right diastolic cardiac function after reduction of emphysema : assessed by the change in the slope end diastolic pressure volume relationship (EDPVR mmHg/ml) obtained by KT Loop procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the change in right systolic heart function</measure>
    <time_frame>1 day</time_frame>
    <description>Estimate the change in right systolic heart function before and after reduction of emphysema assessed by the cardiac output (L/min), the stroke volume (ml), the end systolic pressure (mmHg), the end systolic volume (mmHg), obtained by KT Loop procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the change in right cardiac contractility</measure>
    <time_frame>1 day</time_frame>
    <description>Estimate the change in right cardiac contractility before and after reduction of emphysema assessed by the slope end systolic pressure volume relationship (mmHg/ml), obtained by KT Loop procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate ventriculo-arterial coupling</measure>
    <time_frame>1 day</time_frame>
    <description>Estimate ventriculo-arterial coupling before and after reduction of emphysema assessed by the Ees/Ea ratio, obtained by KT Loop procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the evolution of symptoms assessed</measure>
    <time_frame>1 day</time_frame>
    <description>Evaluate the evolution of symptoms assessed by the Mmrc questionnaire and the CATCOPD questionnaire before and after reduction of emphysema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing exercice performance</measure>
    <time_frame>1 day</time_frame>
    <description>Assessing exercice performance by the 6 minutes walk test before and after reduction of emphysema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the evolution of respiratory function</measure>
    <time_frame>1 day</time_frame>
    <description>Evaluate the evolution of respiratory function before and after reduction of emphysema assessed by the FEV1 (Liters and % of predicted value), the FVC (Liters and % of predicted value), the RV (Liters and % of predicted value), the TLC (Liters and % of predicted value) obtained by spirometry/plethysmography.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COPD</condition>
  <condition>Emphysema</condition>
  <condition>Right Heart Dysfunction</condition>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
    <description>COPD patients with severe emphysema and right heart dysfunction</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients with severe emphysema and right heart dysfunction
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  At least 40 years

          -  A smoking history

          -  Smoking cessation ≥ 6 months

          -  FEV1/FVC ≤ 0,7

          -  Severe emphysema (destruction ≥ 50%)

          -  Peak tricuspid regurgitation velocity &lt; 2,8 m/s or presence of other echocardiographic
             &quot;PH signs&quot;

          -  15% ≤ FEV1post ≤ 50%

          -  Residual volume ≥ 175% predicted

          -  TLC ≥ 100% predicted

          -  Optimal medical management

          -  150m ≤ 6MWD ≤ 500m

          -  mMRC ≥ 2

          -  Physical activity ≥ 2/Week (≥ 30minutes)

        Exclusion criteria:

          -  ≥2 hospitalizations/year for EACOPD

          -  Recent EACOPD (≤ 3months)

          -  ≥ 50ml mucus/day

          -  PAPm ≥35mmHg

          -  PaCO2 ≥ 55mmHg

          -  Bubble ≥ 1/3 hemithorax

          -  Lung fibrosis, bronchiectasis, lung cancer, homolateral surgery

          -  Left ventricular ejection fraction ≤ 45%, unstable heart disease

          -  Life expectancy ≤ 1 year

          -  Contraindication to anesthesia

          -  Allergy to nitinol or silicone

          -  Corticotherapy ≥ 10mg/day

          -  Patient under legal protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Bourdin, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnaud Bourdin, MD PhD</last_name>
    <phone>467336091</phone>
    <phone_ext>33</phone_ext>
    <email>a-bourdin@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Arnaud BOURDIN, MD PhD</last_name>
      <phone>46733609</phone>
      <phone_ext>33</phone_ext>
      <email>a-bourdin@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

